Tests vitamin K2 supplement for adults with episodic migraine
Compares vitamin K2 supplements with placebo in adults with episodic migraine.
Plain-language title generated from the registry record
Registry title: Vitamin K2 Supplementation in Adult Episodic Migraine
Key facts
- Where
- Beirut, LebanonSee the site
Where in Lebanon
- Lebanese American University Medical Center - Rizk HospitalBeirut, LebanonTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sola Aoun Bahous, M.D. Ph.D.
- Trial code
- NCT05943457
- Record updated
- 18 November 2025
- Original description
Migraine is a debilitating illness and a major cause of disability in the world. It is highly prevalent, especially among women. Vitamin supplementation is a potential therapeutic option for migraines that remains largely under-explored. Several studies have shown that people with migraine tend to have higher arterial stiffness than people without migraine. Vitamin K2 deficiency is an important mediator of arterial stiffness and calcification due to decreased carboxylation of matrix Gla protein (MGP). Supplementation reverses these changes and improves vascular health in patients with end stage renal disease according to previous studies. Therefore, vitamin K2 supplementation could serve a potential role in migraine patients. The purpose of the study is to test the effect of vitamin K2 on decreasing the frequency of migraine attacks and decreasing arterial stiffness. The population will be recruited from the neurology clinic at LAU Medical Center-Rizk Hospital and will constitute of adult patients. They will be randomized to receive either the supplement of vitamin K2 or a placebo for the duration of 6 months. Laboratory tests and arterial stiffness measurements will be done at the beginning, middle, and at the end of the study for comparison.Read full original descriptionShow less
Efficacy of Vitamin K2 Supplementation in Adult Episodic Migraine
Migraine is a debilitating illness and a major cause of disability in the world. It is highly prevalent, especially among women. Vitamin supplementation is a potential therapeutic option for migraines that remains largely under-explored. Several studies have shown that people with migraine tend to have higher arterial stiffness than people without migraine. Vitamin K2 deficiency is an important mediator of arterial stiffness and calcification due to decreased carboxylation of matrix Gla protein (MGP). Supplementation reverses these changes and improves vascular health in patients with end stage renal disease according to previous studies. Therefore, vitamin K2 supplementation could serve a potential role in migraine patients. The purpose of the study is to test the effect of vitamin K2 on decreasing the frequency of migraine attacks and decreasing arterial stiffness. The population will be recruited from the neurology clinic at LAU Medical Center-Rizk Hospital and will constitute of adult patients. They will be randomized to receive either the supplement of vitamin K2 or a placebo for the duration of 6 months. Laboratory tests and arterial stiffness measurements will be done at the beginning, middle, and at the end of the study for comparison.
Inclusion: Adults aged 18 years or above; History of episodic migraine with or without aura since > 12 months according to the ICHD-3 criteria; Migraine frequency from 4-14 days per month over the 3 months prior to screening; Migraine frequency from 4-14 days per month during the baseline period of assessment; Successful completion of the migraine diary during the baseline evaluation period.
Exclusion: Patients who have been on any of the previously listed medications within 3 months of screening; Patient who takes the following medications:; Ergotamine or Triptans > 10 days per month; NSAIDs or paracetamol > 15 days per month; Opioids more than 4 days per month; Patients on anticoagulants; Inability to tolerate oral medications; Other active chronic pain syndromes (i.e. fibromyalgia, painful peripheral neuropathy, post-herpetic neuralgia…); History of hypersensitivity to the vitamin K2; History of soy protein, cheese, eggs and meat allergy; History of thrombotic events; Diagnosed coagulopathy or any condition related to coagulation; Known intestinal malabsorption or hypomotility syndromes; Active malignancy; Any acute illness in the past month; Patients who are currently on any of the migraine prophylactic treatments (Sodium valproate, Topiramate, Beta-blockers, Tricyclic antidepressants, SRNI, Flunarizine, Verapamil, Lisinopril, Candesartan); Migraine patients with superimposed tension type or other forms of primary headaches; Cardiovascular event in the past month; Current or planned pregnancy; Lactation; Atrial fibrillation.